Patricia Hill
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,413 and has fallen 61.6% since, to $542 in 2025. Among family clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$527
- Amgen$383
- AstraZeneca$279
- Pfizer$269
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$208
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $1,004 |
| Novo Nordisk | 30 | $527 |
| Amgen | 16 | $383 |
| AstraZeneca | 9 | $279 |
| Pfizer | 15 | $269 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $208 |
| Johnson & Johnson | 2 | $144 |
| Kowa Pharmaceuticals America, Inc. | 2 | $142 |
| Daiichi Sankyo Inc. | 1 | $119 |
| Geron Corporation | 1 | $115 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $107 |
| E.r. Squibb & Sons, L.L.C. | 1 | $107 |
| Seagen Inc. | 1 | $96 |
| Lilly USA, LLC | 5 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Bayer | 1 | $70 |
| Corium, LLC | 3 | $61 |
| Dexcom, Inc. | 3 | $52 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Exact Sciences | 3 | $49 |
| Adlon Therapeutics L.p. | 3 | $44 |
| Merck | 3 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| GSK | 2 | $36 |
| Abbott | 2 | $33 |
| Trevena, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,372 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $85,133 |
| EliquisApixaban | 62 | $51,072 |
| OzempicSemaglutide | 42 | $47,520 |
| LinzessLinaclotide | 42 | $28,644 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $17,640 |
| MyrbetriqMirabegron | 22 | $14,452 |
| TradjentaLinagliptin | 16 | $10,412 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,018 |
| InvokanaCanagliflozin | 11 | $5,823 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,559 |
| Colesevelam Hcl | 12 | $4,642 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $3,551 |
| Gabapentin | 88 | $3,068 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,671 |
| Omeprazole | 143 | $1,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $75 | $85,13367 claims |
| PfizerEliquis | $269 | $51,07262 claims |
| Novo NordiskOzempic | $527 | $47,52042 claims |
| AbbVieLinzess | $1,004 | $28,64442 claims |
| GSKTrelegy Ellipta | $36 | $17,64011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $25 | $6,01812 claims |
| Johnson & JohnsonInvokana | $144 | $5,82311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Macon
- Villanueva SpiveyMacon$18K
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.